<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hamza S</submitter><funding>Russian Federation Presidential Grant</funding><pagination>299</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10975274</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(3)</volume><pubmed_abstract>The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of a pharmacological NLRP3 inhibitor, glibenclamide (gli), and the post-translational suppression of NLRP3 by miR-223 on CRC cell progression in HCT-116 and HCT-15 cells. LPS and ATP were used to activate Gli-treated and LSB-hsa-miR-223-3p (WT&lt;sup>miR-223&lt;/sup&gt;)-expressing HCT-116 cells. NLRP3.AB.pCCL.sin.cPPT.U6.miR-223-Decoy.hPGK.GFP.WPRE plasmid (D&lt;sup>miR-223&lt;/sup>) was the negative control for miR-223 expression. NLRP3, gasdermin D, and BAX expressions were analyzed using western blotting. Real-time PCR detected the RNA expression of autophagy-related genes ATG5, BECN1, and miR-223 in non-transfected cells. ELISA analyzed IL-1β and IL-18 in the medium. MTS-1, annexin V, wound-healing, and sphere-invasion assays were used to assess cell viability and progression. A multiplex cytokine assay detected proinflammatory cytokine secretion. LPS-ATP-activated NLRP3 produced gasdermin D cleavage, released IL-1b and IL-18, and activated cell migration and sphere invasion. In contrast, reduced cell growth, miR-223 expression, IFN-γ, CXCL10, and LIF secretion were found in cells after inflammasome activation. Both gli and WT&lt;sup>miR-223&lt;/sup> induced autophagy genes ATG5 and BECN1 and reduced the NLRP3 activation and its downstream proteins. However, while gli had a limited effect on the production of IFN-γ, CXCL10, and LIF, WTmiR-223 increased the release of those cytokines. In addition, gli did not suppress cell growth, while WTmiR-223 promoted apoptosis. Notably, neither gli nor WTmiR-223 effectively prevented sphere invasion. These data suggest that, while WT&lt;sup>miR-223&lt;/sup> could have a better anticancer effect in CRC compared to gli, the sole usage of miR-223-mediated NLRP3 suppression may not be sufficient to prevent CRC metastasis.</pubmed_abstract><journal>Pharmaceuticals (Basel, Switzerland)</journal><pubmed_title>Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer.</pubmed_title><pmcid>PMC10975274</pmcid><funding_grant_id>#МК-3571.2021.1.4</funding_grant_id><pubmed_authors>Hamza S</pubmed_authors><pubmed_authors>Tezcan G</pubmed_authors><pubmed_authors>Garanina EE</pubmed_authors><pubmed_authors>Shkair L</pubmed_authors><pubmed_authors>Alsaadi M</pubmed_authors><pubmed_authors>Khaiboullina SF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer.</name><description>The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of a pharmacological NLRP3 inhibitor, glibenclamide (gli), and the post-translational suppression of NLRP3 by miR-223 on CRC cell progression in HCT-116 and HCT-15 cells. LPS and ATP were used to activate Gli-treated and LSB-hsa-miR-223-3p (WT&lt;sup>miR-223&lt;/sup&gt;)-expressing HCT-116 cells. NLRP3.AB.pCCL.sin.cPPT.U6.miR-223-Decoy.hPGK.GFP.WPRE plasmid (D&lt;sup>miR-223&lt;/sup>) was the negative control for miR-223 expression. NLRP3, gasdermin D, and BAX expressions were analyzed using western blotting. Real-time PCR detected the RNA expression of autophagy-related genes ATG5, BECN1, and miR-223 in non-transfected cells. ELISA analyzed IL-1β and IL-18 in the medium. MTS-1, annexin V, wound-healing, and sphere-invasion assays were used to assess cell viability and progression. A multiplex cytokine assay detected proinflammatory cytokine secretion. LPS-ATP-activated NLRP3 produced gasdermin D cleavage, released IL-1b and IL-18, and activated cell migration and sphere invasion. In contrast, reduced cell growth, miR-223 expression, IFN-γ, CXCL10, and LIF secretion were found in cells after inflammasome activation. Both gli and WT&lt;sup>miR-223&lt;/sup> induced autophagy genes ATG5 and BECN1 and reduced the NLRP3 activation and its downstream proteins. However, while gli had a limited effect on the production of IFN-γ, CXCL10, and LIF, WTmiR-223 increased the release of those cytokines. In addition, gli did not suppress cell growth, while WTmiR-223 promoted apoptosis. Notably, neither gli nor WTmiR-223 effectively prevented sphere invasion. These data suggest that, while WT&lt;sup>miR-223&lt;/sup> could have a better anticancer effect in CRC compared to gli, the sole usage of miR-223-mediated NLRP3 suppression may not be sufficient to prevent CRC metastasis.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-04-22T21:29:28.56Z</modification><creation>2025-04-06T03:35:23.193Z</creation></dates><accession>S-EPMC10975274</accession><cross_references><pubmed>38543085</pubmed><doi>10.3390/ph17030299</doi></cross_references></HashMap>